EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PDS Biotechnology's enterprise value is $86.87 Mil.
PDS Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-40.13 Mil. Therefore, PDS Biotechnology's EV-to-EBITDA for today is -2.16.
The historical rank and industry rank for PDS Biotechnology's EV-to-EBITDA or its related term are showing as below:
PDSB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.62 Med: 0 Max: 0
Current: -2.16
PDSB's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.1
vs PDSB: -2.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PDS Biotechnology EV-to-EBITDA Historical Data
The historical data trend for PDS Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDS Biotechnology's EV-to-EBITDA
For the Biotechnology subindustry, PDS Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDS Biotechnology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's EV-to-EBITDA falls into.
PDS Biotechnology's current Enterprise Value is $86.87 Mil.
PDS Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PDS Biotechnology's PE Ratio for today is calculated as:
PDS Biotechnology's share price for today is $3.27.
PDS Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PDS Biotechnology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PDS Biotechnology (PDS Biotechnology) Business Description
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDSB has been successfully added to your 